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ABSTRACT 
Background 
Interventions for somatoform disorders typically address a range of outcomes. 
We aimed to examine treatment effects across outcome domains and specifically 
assess the association, at study level, between short and long term treatment 
effects and between treatment effects in different outcome domains.   
Methods 
We used data from recent systematic reviews of interventions for somatoform 
disorders to address three questions: We described outcome domains and 
measures by compiling forest plots of standardised mean difference. We 
examined the association of changes in outcome between short and long-term 
and between different outcome domains by non-parametric correlation. 
Results 
We analysed data from 47 studies across four outcome domains: physical 
symptoms, health-related quality of life, depression and anxiety. Short-term and 
long-term treatment effects within each outcome domain were broadly similar 
and were correlated Reported reduction in physical symptoms was correlated 
with reductions in depression (rho = 0.73, p=0.002) and anxiety (0.70, p<0.001) 
and increase in quality of life (0.54, p=0.03). 
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Conclusion 
Short term changes in outcome measures are correlated with longer term 
changes; outcome changes are correlated across domains independently of the 
type of treatment. 
Keywords 
Somatoform; Medically Unexplained Symptoms; Outcome Measures; 
Interventions; Systematic Review 
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Background 
Somatoform disorders, including medically unexplained symptoms, are 
characterised by patients experiencing physical symptoms which cannot be fully 
explained by organic disease, in multiple body systems, and in a way which 
impairs quality of life and / or increases healthcare use [1].  A number of 
intervention approaches have been evaluated in randomised controlled trials, 
and in turn the findings of these trials have been synthesised in systematic 
reviews of pharmacotherapy[2], psychological interventions[3] and enhanced 
medical consultations[4]. 
 
While future interventions and trials are being developed there is a need to 
ascertain the best outcome measures to use in trials and other evaluations [5-7]. 
Such outcome measures should be validated, accurate and responsive to therapy 
[8]. They should also be of importance to patients [7] and should persist over 
time. The choice of outcome measures has consequences for sample size 
calculation [9](and thus the feasibility and cost of trials) as well as for external 
validity with clinicians and patients. The first step of such a process is typically a 
review of systematic reviews of trials to examine current and past practice [8]. 
 
 
We aimed to conduct a review of three recent Cochrane reviews to address the 
following objectives in relation to trials of interventions for somatoform 
disorders or medically unexplained symptoms. : (1) To describe, in one place, 
which outcome domains (e.g. physical symptoms, depression) were reported and 
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which measures were used? (2) To examine the relationship between short-term 
and long-term treatment effects within outcome domains  (3) To examine the 
association between treatment effects in one outcome domain and treatment 
effects in another.  
Methods 
Overview of methods 
We aimed to use outcome data which had already been extracted, quality-
assessed and summarised for meta-analysis from recent Cochrane reviews of 
interventions for MUS / somatoform disorders. In comparing data across 
reviews, we took the perspective that for any given outcome measure, the effect 
of a study on that outcome would depend on many factors relating to the 
intervention, patients, and setting. Prior reading of the reviews showed that 
there was a high level of conceptual and contextual heterogeneity across the 
studies. Additionally, we recognised that in some instances the type of 
intervention might also influence the choice of measure (for instance studies of 
antidepressant drugs typically include the Hamilton Depression Rating Scale). 
We thus aimed to synthesise data in a way which allowed us to visualise patterns 
of response across a diverse range of interventions [12,13], while stopping short 
of conducting formal statistical meta-analysis to produce summary effects with 
magnitude and precision.  
Data sources 
We extracted data from three systematic reviews of interventions for 
somatoform disorders[2-4]. These had all been published in the preceding three 
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years and related to pharmacological, psychological, and enhanced primary care 
interventions. All three reviews reported outcomes as standardised mean 
difference (SMD)[14] between allocation groups at short (up to 3 months) and 
longer term (nearest to one year) follow-up. 
 
We included data from studies which compared active treatment with an 
inactive control condition (placebo, usual care, waiting list) and from studies 
which compared two active treatments. Where a single active treatment was 
compared with a control condition we extracted SMDs of the active treatment 
relative to the control. Where two active treatments were compared we could 
not make a priori assumptions about which treatment should be more effective, 
so recorded SMDs as favouring the more effective treatment. 
Data extraction and categorisation 
We extracted data from tables in two ways. One reviewer (SC) extracted data 
from studies listed in the reviews manually, another reviewer (CB) electronically 
extracted data from the statistical data tables of the reviews from the Cochrane 
Collaboration website. Any discrepancies were sought out and resolved by 
reference to the original studies. 
 
We sorted individual outcomes into five outcome domains: physical symptoms, 
health-related quality of life, depression, anxiety, and health anxiety. Where 
quality of life measures were reported at both summary and subscale levels (e.g. 
SF-36 physical component summary and physical functioning), we took the most 
inclusive (highest level) measure. While some studies used a quality of life 
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subscale as a measure of physical symptoms, we chose to exclude these from the 
physical symptoms domain as they do not specify number or impact of 
symptoms which are integral to the concept of somatoform disorders.  
 
Description and visualization 
For each outcome domain we summarized the number of studies by review, 
separating short term and long term treatment effects. We plotted these using 
forest plots in which each studys SMD was displayed with 95% confidence 
intervals. We grouped individual studies by the outcome measure used and 
plotted values in ascending order of magnitude within the outcome measure 
group. For each point we indicated the review from which it was taken by the 
symbol for the point value.  As each outcome domain contained different 
numbers of outcome measures, some of which were only used once, we adopted 
a pragmatic approach to grouping small numbers of individual items together in 
other measures categories. We did not carry out meta-analysis either to 
generate summary measures of treatment effect or to provide statistical 
estimation of heterogeneity because of the contextual heterogeneity of 
populations, interventions and measures.  
Relationship of short term to long-term outcomes within study domains  
.We examined the relationship between short and long term treatment effects in 
the subset of studies which reported both short and long term effects, by 
constructing scatter plots of short term vs. long term outcomes and calculating 
the Spearman non-parametric correlation coefficient. We expected that short 
and long term outcomes should be correlated,  but wished to examine the 
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relationship between the two in order to inform the way that short term 
measures (such as from a pilot trial) might be used to guide longer term 
measures (in a definitive study). 
Association of treatment effects between outcome domains 
We examined the correlation between SMDs for pairs of outcome domains, 
where these were both reported in the same study, by constructing scatter plots 
and calculating the Spearman correlation coefficient.  For the scatter plots, we 
used plotting symbols to distinguish points from different reviews and showed 
the best fitting regression line for all studies and for the non-pharmacological 
studies. As there were relatively few studies from each review, we did not 
calculate correlations separately. As the number of studies reporting long-term 
data was relatively small, we only used short term outcome data for this 
correlation analysis. 
Sensitivity analysis 
We identified a number of studies in the review of pharmacotherapy which 
compared two active drug treatments. We included them in the forest plots of 
treatment effects but used a different symbol to identify them from the others in 
the same review. None of these studies reported long term treatment effects. We 
conducted a sensitivity analysis of the association of treatment effects between 
domains with them excluded.  
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Results 
Outcome domains and measures 
The three reviews contained tabulated data from a total of 47 studies 
(Kleinstauber [2] 23, van Dessel [3]18, Rosendal[4] 6,). They reported data on 
172 outcomes across the five outcome domains. Table 1 summarises the 
distribution of these outcomes by review, outcome domain and the timing of the 
outcome in relation to treatment as either short term (typically post-treatment) 
or long term. A more extensive table in which these are broken down by measure 
used at individual study level is in Appendix 1.  
 
There were several outcome measures (instruments) used for physical 
symptoms (9), depression (9) and anxiety (6).  There were fewer measures for 
quality of life (most studies used one of the SF- family of instruments). Health 
anxiety was reported for only four studies, all with one of the forms of the 
Whitely index.  Because of this, we excluded it from further analysis and 
reporting. Most studies used existing and well-validated measures such as the 
Hamilton rating scales [15], the Symptoms Checklist[16], Beck inventories[17] or 
scales from the Personal Health Questionnaire[18]. Only 10/172 outcomes used 
either unspecified (5) or idiosyncratic (5) outcome measures; a further two used 
a visual analog scale for one of the outcomes. 
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Differences in reported treatment effects by domain and measure 
Figure 1 shows the treatment effects of each study, expressed as standardized 
mean difference (SMD), for short term or post-treatment outcomes. Similar plots 
for long-term outcomes are in appendix 2.  
 
Only 19 studies (40%) reported long term outcomes. None of the 
pharmacological studies reported long term outcomes. One study reported long 
term outcomes but no short term outcomes. Short and long-term treatment 
effects were correlated for all outcome domains: physical symptoms (rho = 0.78, 
p<0.01); depression (rho = 0.79, p<0.01); anxiety (rho =0.94, p=0.02); quality of 
life (rho = 0.85, p<0.01). Scatter plots of these associations are shown in figure 2. 
For these studies which reported both short and long term outcomes, the median 
(IQR) SMD at the two points was for physical symptoms -0.23 (-0.51 to 0.13) and 
-0.20 (-0.37 to -0.03), 16 studies; for quality of life +0.16 (0.08 to 0.25) and +0.16 
(0.10 to 0.27), 11 studies; and for depression -0.05 (-0.25 to 0.07) and -0.09 (-
0.20 to 0.09), 15 studies. Only 6 studies reported short and long-term outcomes 
for anxiety (median SMD 0.22 and 0.09 respectively). 
 
 
Correlation between treatment effects in pairs of outcome domains 
The plots in figure 3 demonstrate the correlation of treatment effects between 
domains. The correlations shown between SMD for physical symptoms and SMD 
for depression, anxiety and quality of life at the study level were all statistically 
significant: Spearman rho = 0.73 (p<0.01); 0.70 (p<0.01) and -0.54 (p=0.03) 
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respectively. Unsurprisingly, there was also a strong correlation between SMD 
for anxiety and SMD for depression (rho = 0.83, p<0.01). In the sensitivity 
analysis which excluded studies comparing two active treatments, correlations 
between SMD for physical symptoms and SMD for depression, anxiety and 
quality of life at the study level were all similar: Spearman rho = 0.71, 0.73 and   -
0.54 respectively 
Discussion 
Summary of main findings 
When we compared the outcomes of trials across a wide range of interventions 
for, and populations with, somatoform disorders, we found correlations both 
between short and long term outcomes and between different outcome domains. 
This association appeared to be independent of the treatment type.  
Strengths and limitations 
A key strength of this study is that the data had already undergone careful 
selection, assessment of study quality and preparation for synthesis by the 
authors of the original reviews. The study took as an underlying rationale, the 
idea, compatible with a critical realist scientific approach, that consistent 
processes may underpin observed data across a wide range of contexts [12,13]. 
While the data were too heterogeneous to conduct a network meta-analysis we 
used non-parametric statistics to examine patterns across studies. Nevertheless, 
the heterogeneity of the studies is a limitation. In particular, the review of 
pharmacotherapy included several studies focusing on chronic pain in treatment 
naïve patients which showed large treatment effects, mostly using the same 
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measure (Hamilton rating scale), however as these studies generally only 
reported short term outcomes for one domain, their inclusion or exclusion did 
not influence the correlations reported here,  We considered extending the 
review by including data from reviews of specific functional somatic syndromes 
such as fibromyalgia which has well developed and validated syndrome-specific 
outcome measures [19]. We chose not to include these because such measures 
typically include multiple domains such as symptoms, functional impairment and 
emotional / psychological factors. The outcome measures reported here reflect 
those reported in the systematic reviews, and does not include others which 
were more difficult to compare across studies (e.g. health service use or costs).  
Relationship to other studies 
In comparing measures of treatment effects within and between outcome 
domains for a heterogeneous set of studies, this project takes an original 
approach which is neither a network meta-analysis [10] nor a multi-system 
review [11]. Rather it takes an approach which, while quantitative, has parallels 
with the qualitative approach taken in realist evaluation [13]: the emphasis is on 
common processes across contexts [12] rather than restriction of analysis to 
tightly defined contexts. Our findings of strong correlations at the study level 
between diverse outcomes (physical symptoms, anxiety and depression) 
suggests that despite working through diverse mechanisms (e.g. antidepressant 
drugs, behavioural interventions focused on symptoms) interventions appear to 
produce common outcomes. It is possible that similar associations across 
outcome domains would be seen in other conditions, such as arthritis, but we are 
not aware of research comparing them.  
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Implications  
In planning evaluation of future interventions, researchers need to consider 
which domains and measures to use as primary and secondary study outcomes 
[8,9]. At first glance, the different outcomes studied may appear to be similar, 
however a closer look at the studies shows three things of importance. First, 
short term treatment effects appear to be sustained to longer term outcomes, at 
least for physical symptoms and quality of life. This is important as 
developmental and pilot studies of interventions may have limited follow-up. 
While sustained benefit from interventions requires testing, short term effects 
can reasonably be used to plan sample size calculations.  Second, treatment 
effects in one domain are correlated with effects in others, suggesting non-
specific treatment effects across different intervention types. Third, most 
treatment effects are small. With median SMD of 0.2-0.3 these are at the lower 
limits of clinical usefulness. It is not clear whether this modest effect represents 
a limitation of the interventions or of the outcome measures. Approaches to 
outcome measurement such as responder analysis [20] which examine 
individual responses within a study population may be informative in this 
regard.  
 
Further work is needed to develop a core outcome measure set for trials of 
interventions. While for specific functional syndromes, there is a good case for 
using a composite outcome measure which covers many domains (e.g. the 
fibromyalgia impact questionnaire [19]), the alternative for heterogeneous 
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populations of patients with somatoform disorders may be a suite of measures 
covering a range of domains. [21] 
Conclusion 
Trials of interventions for somatoform disorders across differing interventions 
and study populations show broadly similar distributions of treatment effects in 
each of the major outcome domains. Importantly, short term treatment effects 
are correlated with longer term effects in all major treatment domains and 
effects in one domain are correlated with effects in others.  
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Table 1 Distribution of outcomes reported by domain, review and timing in relation to treatment 
 Kleinstauber Rosendal vanDessel Total 
 Short term Long term Short term Long term Short term Long term Short term Long term 
Anxiety 11 0 3 2 7 4 21 6 
Depression 18 0 5 4 15 11 38 15 
Health Anxiety 0 0 4 3 0 0 4 3 
QOL 3 0 4 4 12 8 19 12 
Symptoms 17 0 4 5 16 12 37 17 
 49 0 20 18 50 35 119 53 
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Figure 1 Forest plots of short term treatment effects by measurement 
instrument within outcome domain 
 
Names in the legend refer to the first author of the respective reviews. Kleinstauber(a) refers to 
studies from the review of pharmacotherapy which compared two drugs. 
Abbreviations: BDI, Beck Depression Inventory; HAD, Hospital Anxiety & Depression Scale; 
HAM, Hamilton Depression / Anxiety Rating Scale; PHQ Personal Health Questionnaire; SCL, 
Johns Hopkins Symptoms Checklist; SOM, Screening for Somatoform Symptoms; SF-, Medical 
Outcomes Study Short Form-6, 12 or 36  
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Figure 2 Comparison of short term and long term SMDs for studies, by 
outcome domain 
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Figure 3 Relationship between treatment effects in different outcome 
domains by study and review. 
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